Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
暂无分享,去创建一个
[1] S. Rosenberg,et al. Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma , 2002, The Journal of Immunology.
[2] K. Mori,et al. Socius Is a Novel Rnd GTPase-Interacting Protein Involved in Disassembly of Actin Stress Fibers , 2002, Molecular and Cellular Biology.
[3] J. Nesland,et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] S. Shichijo,et al. Molecular basis of T cell-mediated recognition of pancreatic cancer cells. , 2001, Cancer research.
[5] P. Robbins,et al. A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.
[6] P. Kuppen,et al. T cell responses in colorectal cancer patients: Evidence for class II HLA‐restricted recognition of shared tumor‐associated antigens , 2000, International journal of cancer.
[7] H. Rammensee,et al. SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.
[8] K. Shirouzu,et al. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. , 1999, Cancer research.
[9] S. Rosenberg,et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.
[10] D. Harrington. The tea leaves of small trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Hanna,et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.
[12] T. Lybrand,et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. , 1998, Journal of immunology.
[13] M. Ogawa,et al. Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus , 1998, Cancer Immunology, Immunotherapy.
[14] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[15] K. Haruma,et al. Combined Expression of HLA-DR Antigen and Proliferating Cell Nuclear Antigen Correlate with Colorectal Cancer Prognosis , 1998, Oncology.
[16] J. Witte,et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[18] J. Schlom,et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] M. Olivier,et al. Tyrosine kinase and cAMP‐dependent protein kinase activities in CD40‐activated human B lymphocytes , 1996, European journal of immunology.
[20] J. Turnay,et al. Characterization of tumorigenic sub‐lines from a poorly tumorigenic human colon‐adenocarcinoma cell line , 1996, International journal of cancer.
[21] J. Bodmer,et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. , 1996, Tissue antigens.
[22] A. Sette,et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.
[23] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[24] N. Chakraborty,et al. Immunobiology and immunotherapy of melanoma , 1995, Current opinion in oncology.
[25] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[26] P. Mingazzini,et al. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. , 1992, International surgery.
[27] M. Hanna,et al. Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficacy. , 1992, Cancer research.
[28] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[29] M. Probst-Kepper,et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.
[30] P. Coulie,et al. Antitumor immunity at work in a melanoma patient. , 1999, Advances in cancer research.
[31] E. Appella,et al. A Mutated f3-Catenin Gene Encodes a Melanoma-specifi c Antigen Recognized by Tumor Infiltrating Lymphocytes By Paul F. tLobbins,* Mona E1-Gamil,* Yong F. Li,* , 1996 .
[32] J. Jacobson,et al. Colorectal cancer: Detection, treatment, and rehabilitation , 1994, CA: a cancer journal for clinicians.